Clinical trial
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary…
NCT00083096 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Unknown status
Key facts
| NCT number | NCT00083096 |
|---|---|
| Title | Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas |
| Official title | Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | lonafarnib, temozolomide |
| Enrollment | 30 |
| Start date | Mar 1, 2004 |
| Primary completion | Jun 1, 2009 |
| First posted | May 17, 2004 |
| Last update posted | Feb 10, 2015 |
| Countries | France, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: